GLP-1 Receptor Agonists May Improve Survival for Brain Metastasis Patients with Type 2 Diabetes

Patients with brain metastases and Type 2 diabetes who utilize glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may experience a significantly reduced risk of death, according to a 2026 retrospective cohort study. The study, published in JAMA Network Open, found that GLP-1 RA use was associated with a near 40% lower risk of death over three years compared to non-users.¹

The Link Between Brain Metastases, Type 2 Diabetes, and GLP-1 RAs

Brain metastases, secondary tumors that form in the brain when cancer cells spread from a primary site, are associated with substantial morbidity and mortality.^{2, 3} The presence of Type 2 diabetes can worsen outcomes for these patients through metabolic and inflammatory pathways. GLP-1 RAs, initially developed to manage blood sugar in Type 2 diabetes, may offer a protective effect by combating these pathways and potentially offering neuroprotective and anti-inflammatory benefits.⁴

Study Findings: A 37% Reduction in Mortality Risk

Researchers analyzed data from 850 adult patients diagnosed with brain metastases and Type 2 diabetes between January 1, 2018, and January 1, 2024.¹ All patients had been prescribed a GLP-1 RA within six months of their initial diagnoses. The study excluded individuals with lower socioeconomic status or contraindications to GLP-1 RA use.

The analysis revealed a 37% lower risk of death among patients using GLP-1 RAs. This benefit remained consistent across various cancer types and with different GLP-1 RA medications, with the exception of liraglutide. Importantly, GLP-1 RAs demonstrated a survival advantage even when compared to other antidiabetic therapies.¹

How GLP-1 RAs May Protect the Brain

Beyond their well-established role in glucose control, GLP-1 receptor agonists are increasingly recognized for their broader biological effects. Research suggests that activating GLP-1 receptors influences neurobiological pathways crucial for brain health.⁴ Specifically, GLP-1 RAs may assist preserve the integrity of the blood-brain barrier (BBB), a critical defense mechanism that regulates the passage of molecules between the bloodstream and the central nervous system.⁴ Maintaining BBB stability can potentially impede the invasion and progression of cancer cells within the brain.

Study Limitations and Future Research

The researchers acknowledge that the retrospective study design limits the ability to establish a direct causal link between GLP-1 RA use and improved survival. The available data lacked certain patient details, preventing more detailed analyses, such as dose-response assessments.¹ The study population was as well drawn primarily from academic hospitals, which may limit the generalizability of the findings to non-academic healthcare settings.

Future prospective studies are needed to further investigate the specific effects of GLP-1 RAs in patients with cancer and brain metastases. These studies will help clarify the mechanisms underlying the observed survival benefits and identify which patients are most likely to respond to this treatment approach.¹

Key Takeaways

• GLP-1 RA use is associated with a significantly lower risk of death in patients with brain metastases and Type 2 diabetes.
• The benefit appears consistent across different cancer types and GLP-1 RA medications (excluding liraglutide).
• GLP-1 RAs may protect the brain by preserving the integrity of the blood-brain barrier.
• Further research is needed to confirm these findings and determine the optimal use of GLP-1 RAs in this patient population.

References

1. Chi K-Y et al. GLP-1 receptor agonist use and survival among patients with Type 2 diabetes and brain metastases. JAMA Netw Open. 2026;DOI:10.1001/jamanetworkopen.2026.1311.
2. Mayo Clinic. Brain metastases. 2024. Accessed March 14, 2026.
3. Boire A et al. Brain metastasis. Nat Rev Cancer. 2020;20(1):4-11.
4. Farmaki P et al. Complications of the type 2 diabetes mellitus. Curr Cardiol Rev. 2020;16(4):249-251.